Tisch MS News

Construction crews have arrived on site. The build-out has begun!
The Tisch MS Research Center will be closed on Friday, December 30th, 2016 and Monday, January 2nd, 2017. The Center will re-open on Tuesday, January 3rd, 2017. We wish all of our patients, friends and supporters a safe holiday weekend and a wonderful year to come!
The Tisch MS Research Center will be closed Friday, December 23rd and Monday, December 26th. The Center will re-open on Tuesday, December 27th. We wish all of our patients, friends and supporters a happy, safe and healthy holiday weekend!
Tisch MSRCNY is preparing for construction to commence January 2017 of a state-of-the-art stem cell facility on our 3rd floor. This could not have been done without the generosity of our supporters. The build-out of our new research laboratory enables Phase II of the Tisch MSRCNY FDA-approved stem cell clinical trial to move forward. We are NOT enrolling patients in the study at this time. We anticipate the trial to commence in June of 2017.  Please check the Phase II Page of this website for continuous updates in the coming months. 
Did you know you’re leaving valuable donations toward a Future Without MS on the table every time you shop on Amazon without connecting to Amazon Smile? What is AmazonSmile?   
The Tisch MS Research Center of New York will close at 2:00pm on Wednesday, November 23rd and remain closed through the weekend for Thanksgiving. We wish our friends, supporters and patients a very happy and healthy holiday weekend. The Center will re-open on Monday, November 28th, 2016.
Stars Come Out to Help End Multiple Sclerosis at Tisch MS Research Center of New York’s Future Without MS Gala New York, NY- November 1, 2016- The Tisch MS Research Center of New York (Tisch MSRCNY) announced today that their continued efforts to raise $10 million for the Center’s unprecedented stem cell research received a major boost. Legendary musician Paul Shaffer and star comedian Amy Schumer actively participated in support of their annual Future Without MS Gala at The Plaza Hotel on October 27th, 2016 raising 2.5 million dollars for MS research.
The following article describes the first clinical use of of intrathecal MSC-NPs in 6 patients with progressive MS. An average followup of 7 years demonstrated both short and long term safety of the treatment. Four of the six patients showed a measurable clinical improvement following MSC-NP treatment. The data obtained from this pilot study formed the basis of the FDA approval to conduct a phase I study of MSC-NP treatment in 20 patients. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.


Subscribe to MSRCNY News